Lee Christoph I, Bogart Andy, Germino Jessica C, Goldman L Elizabeth, Hubbard Rebecca A, Haas Jennifer S, Hill Deirdre A, Tosteson Anna Na, Alford-Teaster Jennifer A, DeMartini Wendy B, Lehman Constance D, Onega Tracy L
Dept of Radiology, University of Washington School of Medicine; 825 Eastlake Avenue East, Seattle, WA 98109 Dept of Health Services, University of Washington School of Public Health; 825 Eastlake Avenue East, Seattle, WA 98109
Group Health Research Institute; 1730 Minor Avenue #1600, Seattle, WA, 98101.
J Med Screen. 2016 Mar;23(1):24-30. doi: 10.1177/0969141315591616. Epub 2015 Jun 15.
Among vulnerable women, unequal access to advanced breast imaging modalities beyond screening mammography may lead to delays in cancer diagnosis and unfavourable outcomes. We aimed to compare on-site availability of advanced breast imaging services (ultrasound, magnetic resonance imaging [MRI], and image-guided biopsy) between imaging facilities serving vulnerable patient populations and those serving non-vulnerable populations.
73 imaging facilities across five Breast Cancer Surveillance Consortium regional registries in the United States during 2011 and 2012.
We examined facility and patient characteristics across a large, national sample of imaging facilities and patients served. We characterized facilities as serving vulnerable populations based on the proportion of mammograms performed on women with lower educational attainment, lower median income, racial/ethnic minority status, and rural residence.We performed multivariable logistic regression to determine relative risks of on-site availability of advanced imaging at facilities serving vulnerable women versus facilities serving non-vulnerable women.
Facilities serving vulnerable populations were as likely (Relative risk [RR] for MRI = 0.71, 95% Confidence Interval [CI] 0.42, 1.19; RR for MRI-guided biopsy = 1.07 [0.61, 1.90]; RR for stereotactic biopsy = 1.18 [0.75, 1.85]) or more likely (RR for ultrasound = 1.38 [95% CI 1.09, 1.74]; RR for ultrasound-guided biopsy = 1.67 [1.30, 2.14]) to offer advanced breast imaging services as those serving non-vulnerable populations.
Advanced breast imaging services are physically available on-site for vulnerable women in the United States, but it is unknown whether factors such as insurance coverage or out-of-pocket costs might limit their use.
在易受伤害的女性群体中,除了乳腺钼靶筛查之外,无法平等获得先进的乳腺成像检查可能会导致癌症诊断延迟和不良后果。我们旨在比较为易受伤害患者群体服务的成像机构与为非易受伤害群体服务的成像机构之间先进乳腺成像服务(超声、磁共振成像[MRI]和图像引导活检)的现场可及性。
2011年和2012年期间,美国乳腺癌监测联盟五个区域登记处的73家成像机构。
我们研究了大量全国性成像机构样本及其所服务患者的机构和患者特征。我们根据接受乳腺钼靶检查的女性的教育程度较低、收入中位数较低、种族/族裔少数群体身份以及农村居住情况,将这些机构界定为为易受伤害群体服务。我们进行多变量逻辑回归分析,以确定为易受伤害女性群体服务的机构与为非易受伤害女性群体服务的机构相比,现场提供先进成像检查的相对风险。
为易受伤害群体服务的机构提供先进乳腺成像服务的可能性与为非易受伤害群体服务的机构相同(MRI的相对风险[RR]=0.71,95%置信区间[CI]为0.42,1.19;MRI引导活检的RR=1.07[0.61,1.90];立体定向活检的RR=1.18[0.75,1.85]),或者更有可能(超声的RR=1.38[95%CI为1.09,1.74];超声引导活检的RR=1.67[1.30,2.14])。
在美国,先进的乳腺成像服务在现场可为易受伤害的女性群体提供,但保险覆盖范围或自付费用等因素是否会限制其使用尚不清楚。